IP Library › Granted Patent US 7,034,160
Granted Patent B2
US 7,034,160 · App. 10/404,678 · Granted Apr 25, 2006

Crystalline forms of a factor Xa inhibitor

Assignee: Aventis Pharmaceuticals Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,034,160
App. No.
10/404,678
Granted
Apr 25, 2006
Kind
B2
Abstract

The present invention relates to novel crystalline forms of an inhibitor of Factor Xa, processes for its preparation, compositions comprising it, and its therapeutic use.

Claims (4)

1. A crystalline form of (2R,3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1 -oxido-4-pyridinyl)benzoyl]amino }butanoate hydrochloride, 2-butanol hemisolvate according to the formula

2. The crystalline form of claim 1 having an x-ray powder diffraction pattern which comprises two or more 2θ values selected from 5.0±0.2, 14.8±0.2, 15.1±0.2, 15.8±0.2, 16.6±0.2, 17.7±0.2, 17.9±0.2, 19.6±0.2, 24.9±0.2, 25.0±0.2, and 27.0±0.2.

3. The crystalline form according to claim 1 wherein 2-BuOH is (S)-(+)-2-butanol.

4. The crystalline form according to claim 1 , wherein 2-BuOH is (R)-(−)-2-butanol.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 30, 2004
From: AVENTIS PHARMACEUTICALS INC.
To: AVENTIS PHARMA DEUTSCHLAND GMBH
Reel/Frame 014473/0269 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2003
From: WOODWARD, RICK G.; TEAGER, DAVID S.
To: AVENTIS PHARMACEUTICALS INC.
Reel/Frame 013965/0077 →
Priority Claims (1)
GB 0108903 · Apr 10, 2001 · national
Continuity (3)
Continuation PCTUS013108700 · Oct 4, 2001
Provisional Application 6023831600 · Oct 5, 2000
Related Publication 20030225144A1 · Dec 4, 2003